1.
Weinberg, R. A. The biology of cancer. (Garland Science, 2014).
2.
Hanahan, D. & Weinberg, R. A. The Hallmarks of Cancer. Cell 100, 57–70 (2000).
3.
Lazebnik, Y. What are the hallmarks of cancer? Nature Reviews Cancer 10, 232–233 (2010).
4.
Jeggo, P. A., Pearl, L. H. & Carr, A. M. DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer 16, 35–42 (2015).
5.
Roos, W. P., Thomas, A. D. & Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer 16, 20–33 (2015).
6.
Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).
7.
Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907 (2007).
8.
Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine 363, 711–723 (2010).
9.
Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science 331, 1565–1570 (2011).
10.
Topalian, S. L. et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine 366, 2443–2454 (2012).
11.
Grupp, S. A. et al. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine 368, 1509–1518 (2013).
12.
Robbins, P. F. et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology 29, 917–924 (2011).
13.
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
14.
Klebanoff, C. A., Rosenberg, S. A. & Restifo, N. P. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine 22, 26–36 (2016).
15.
Morris, E. C. & Stauss, H. J. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood 127, 3305–3311 (2016).
16.
de Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology 13, 607–615 (2012).
17.
zur Hausen, H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology 384, 260–265 (2009).
18.
Ajila, V., Shetty, H., Babu, S., Shetty, V. & Hegde, S. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. Journal of Sexually Transmitted Diseases 2015, 1–5 (2015).
19.
Spurgeon, M. E. & Lambert, P. F. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. Virology 435, 118–130 (2013).
20.
Wendzicki, J. A., Moore, P. S. & Chang, Y. Large T and small T antigens of Merkel cell polyomavirus. Current Opinion in Virology 11, 38–43 (2015).
21.
Schinzari, V., Barnaba, V. & Piconese, S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clinical Microbiology and Infection 21, 969–974 (2015).
22.
Lingyun Geng. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. International Journal of Clinical and Experimental Medicine 8, (2015).
23.
Weiss, R. A. & Vogt, P. K. 100 years of Rous sarcoma virus. The Journal of Experimental Medicine 208, 2351–2355 (2011).
24.
Matsuoka, M. & Jeang, K.-T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 30, 1379–1389 (2011).
25.
Pierangeli, A., Antonelli, G. & Gentile, G. Immunodeficiency-associated viral oncogenesis. Clinical Microbiology and Infection 21, 975–983 (2015).
26.
Reichert, J. M. Antibodies to watch in 2017. mAbs 9, 167–181 (2017).
27.
Reichert, J. M. Antibodies to watch in 2016. mAbs 8, 197–204 (2016).
28.
Ecker, D. M., Jones, S. D. & Levine, H. L. The therapeutic monoclonal antibody market. mAbs 7, 9–14 (2015).
29.
Reichert, J. M. Marketed therapeutic antibodies compendium. mAbs 4, 413–415 (2012).
30.
Varghese, S. & Rabkin, S. D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy 9, 967–978 (2002).
31.
Russell, S. J., Peng, K.-W. & Bell, J. C. Oncolytic virotherapy. Nature Biotechnology 30, 658–670 (2012).
32.
Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery 14, 642–662 (2015).
33.
Larson, C. et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 6, (2015).
34.
Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 12, 269–281 (2012).
35.
Gill, S. & June, C. H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews 263, 68–89 (2015).
36.
Barrett, D. M., Grupp, S. A. & June, C. H. Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street. The Journal of Immunology 195, 755–761 (2015).
37.
Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nature Reviews Cancer 12, 265–277 (2012).